TokenPost topic

Lung Cancer

1 TokenPost story is tagged Lung Cancer. The newest appear first.

Latest Lung Cancer stories

• Eli Lilly’s Olomorasib Posts a 62% Response Rate in Lung Cancer Study

  The 77-patient combination group had median progression-free survival of 11.6 months. First randomized Phase 3 data are expected in the first half of 2027.

  Oct 26, 2026, 6:50 AM EDT · Business